Article Text

PDF
Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al
  1. Richard Conway1,2,
  2. Ursula Fearon3,
  3. Eamonn S Molloy1
  1. 1 Centre for Arthritis and Rheumatic Diseases, St. Vincent’s University Hospital, Dublin Academic Medical Centre, Dublin, Ireland
  2. 2 CARD Newman Research Fellow, University College Dublin, Dublin, Ireland
  3. 3 Department of Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland
  1. Correspondence to Dr Richard Conway, Centre for Arthritis and Rheumatic Diseases, St Vincent’s University Hospital, Dublin Academic Medical Centre, Elm Park, Dublin, Ireland; drrichardconway{at}gmail.com

Statistics from Altmetric.com

We thank Samson et al for their interest in our article on ustekinumab in giant-cell arteritis (GCA) and for their comments on our study.1 2 Our initial pilot study reported promising results with the use of ustekinumab in refractory GCA.1

GCA is associated with considerable disease-related and treatment-related morbidity.3 4 While glucocorticoids remain the cornerstone of treatment, the associated increased rates of adverse events such as fractures, sepsis, hypertension and diabetes mellitus are significant concerns to both physicians and patients.4 There is a critical unmet need for new treatment options in GCA to minimise the cumulative glucocorticoid burden …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles